Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 651 to 660 of 1904

TitleReference numberPublishedLast updated
Dapagliflozin for treating chronic heart failure with reduced ejection fractionTA679
Metreleptin for treating lipodystrophyHST14
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA673
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)TA675
Trabectedin for the treatment of advanced soft tissue sarcomaTA185
Mepolizumab for treating severe eosinophilic asthmaTA671
Brolucizumab for treating wet age-related macular degenerationTA672
Leukomed Sorbact for preventing surgical site infectionMTG55
Brain tumours (primary) and brain metastases in over 16sNG99

Results per page

  1. 10
  2. 25
  3. 50
  4. All